Automate Your Wheel Strategy on ABUS
With Tiblio's Option Bot, you can configure your own wheel strategy including ABUS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ABUS
- Rev/Share 0.0336
- Book/Share 0.4151
- PB 8.5528
- Debt/Equity 0.015
- CurrentRatio 6.0114
- ROIC -0.9313
- MktCap 679920850.0
- FreeCF/Share -0.3083
- PFCF -11.5646
- PE -8.8416
- Debt/Assets 0.0102
- DivYield 0
- ROE -0.7546
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
Read More
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, …
Read More
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
Read More
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Read More
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Read More
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D.
Read More
About Arbutus Biopharma Corporation (ABUS)
- IPO Date 2007-07-26
- Website https://www.arbutusbio.com
- Industry Biotechnology
- CEO Ms. Lindsay Androski J.D., M.B.A.
- Employees 44